Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial-Reference-Cited by-同舟云学术

Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial

Published:2024-09-11 Issue:1 Volume:14 Page:
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer J.

Author:

McCurdy Arleigh^ORCID,Reece Donna^ORCID,Louzada Martha L.,White Darrell,Parkin Stephen,Chu Michael P.,Kotb Rami,Mian Hira,Othman Ibraheem,Su Jiandong,Khan Aniba,Gul Engin^ORCID,Trudel Suzanne

Funder

Study was sponsored by the Canadian Myeloma Research Group (CMRG) with support from Glaxo-Smith-Kline

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41408-024-01135-2.pdf

Reference43 articles.

1. Mian H, Reece D, Masih-Khan E, McCurdy A, Kardjadj M, Jimenez-Zepeda VH, et al. Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007–2018: Retrospective Analysis from the Canadian Myeloma Research Group Database. Clin Lymphoma Myeloma Leuk. 2022;22:608–17.

2. Puertas B, González-Calle V, Sobejano-Fuertes E, Escalante F, Queizán JA, Bárez A, et al. Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma. Cancers. 2023;15:1558.

3. McCurdy A, Seow H, Pond GP, Gayowsky A, Chakraborty R, Visram A, et al. Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study. Haematologica. 2023;108:3384–91.

4. Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, et al. Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. N Engl J Med. 2022;387:132–47.

5. Moreau P, Hulin C, Macro M, Caillot D, Chaleteix C, Roussel M, et al. VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. Blood. 2016;127:2569–74.